The reported statements, read against the company's own industry.
Financials view
Market Capitalization
5.67BUSD
vs all stocks (USD)
Updated Sep 27, 2026
Revenue (TTM)
165.26MUSD
vs all stocks (USD)
Updated Sep 27, 2026
Profit Margin
-236.95%
vs Diagnostics & Research peers
Updated Sep 27, 2026
Beta
3.25x
vs all stocks
Updated Sep 27, 2026
52-Week Change
115.91%
vs all stocks
Updated Sep 27, 2026
Market Capitalization
5.67BUSD
vs all stocks (USD)
Updated Sep 27, 2026
Enterprise Value
4.90BUSD
vs all stocks (USD)
Updated Sep 27, 2026
Forward P/E
-14.22x
vs Diagnostics & Research peers
Updated Sep 27, 2026
Price to Sales (TTM)
34.30x
vs Diagnostics & Research peers
Updated Sep 27, 2026
Price to Book (MRQ)
2.23x
vs Diagnostics & Research peers
Updated Sep 27, 2026
Enterprise to Revenue
29.63x
vs Diagnostics & Research peers
Updated Sep 27, 2026
Enterprise to EBITDA
-12.94x
vs Diagnostics & Research peers
Updated Sep 27, 2026
Gross Margin
-28.12%
vs Diagnostics & Research peers
Provider-reported. Gross Profit (TTM) ÷ Revenue (TTM) on this page gives 49.71%.Updated Sep 27, 2026
Profit Margin
-236.95%
vs Diagnostics & Research peers
Updated Sep 27, 2026
Operating Margin
-332.00%
vs Diagnostics & Research peers
Updated Sep 27, 2026
Return on Assets (TTM)
-12.03%
vs Diagnostics & Research peers
Updated Sep 27, 2026
Return on Equity (TTM)
-16.12%
vs Diagnostics & Research peers
Updated Sep 27, 2026
Revenue (TTM)
165.26MUSD
vs all stocks (USD)
Updated Sep 27, 2026
Revenue per Share (TTM)
4.11USDUpdated Sep 27, 2026
Quarterly Revenue Growth
25.70%
vs Diagnostics & Research peers
Updated Sep 27, 2026
Gross Profit (TTM)
82.15MUSD
vs all stocks (USD)
Updated Sep 27, 2026
EBITDA (TTM)
-378.49MUSD
vs all stocks (USD)
Updated Sep 27, 2026
Net Income (TTM)
-391.59MUSD
vs all stocks (USD)
Updated Sep 27, 2026
Quarterly Earnings Growth (YoY)
25.72%
vs Diagnostics & Research peers
Updated Sep 27, 2026
Operating Cash Flow (TTM)
-294.75MUSD
vs all stocks (USD)
Updated Sep 27, 2026
Levered Free Cash Flow (TTM)
-103.58MUSD
vs all stocks (USD)
Updated Sep 27, 2026
Trailing Annual Dividend Rate
0.00USDUpdated Sep 27, 2026
Trailing Annual Dividend Yield
0.00%
vs all stocks
Updated Sep 27, 2026
Payout Ratio
0.00%
vs Diagnostics & Research peers
Updated Sep 27, 2026
Revenue
147.17MUSDFY2025 · Dec 31, 2025
Cost of Goods Sold
209.75MUSDFY2025 · Dec 31, 2025
Gross Profit
-62.57MUSDFY2025 · Dec 31, 2025
Operating Income
-534.16MUSD
vs all stocks (USD)
FY2025 · Dec 31, 2025
Pre-tax Income
-534.50MUSDFY2025 · Dec 31, 2025
Income Tax Expense
-126.15MUSDFY2025 · Dec 31, 2025
Net Income
-408.35MUSDFY2025 · Dec 31, 2025
EBIT
-534.16MUSDFY2025 · Dec 31, 2025
EBITDA (Income Statement)
-349.82MUSDFY2025 · Dec 31, 2025
Research & Development
195.79MUSDFY2025 · Dec 31, 2025
Selling, General & Administrative
275.80MUSDFY2025 · Dec 31, 2025
Non-operating Interest Income
28.65MUSDFY2025 · Dec 31, 2025
EPS (Basic)
-11.11USDFY2025 · Dec 31, 2025
EPS (Diluted)
-11.11USDFY2025 · Dec 31, 2025
Basic Shares Outstanding
36.75MSharesFY2025 · Dec 31, 2025
Diluted Shares Outstanding
36.75MSharesFY2025 · Dec 31, 2025
Net Income from Continuing Operations
-408.35MUSDFY2025 · Dec 31, 2025
Operating Cash Flow
-315.94MUSDFY2025 · Dec 31, 2025
Free Cash Flow
-316.85MUSDFY2025 · Dec 31, 2025
Cash & Cash Equivalents (End of Period)
256.70MUSDFY2025 · Dec 31, 2025
Starting Profit (CF Statement)
-408.35MUSDFY2025 · Dec 31, 2025
Depreciation & Amortization
156.34MUSDFY2025 · Dec 31, 2025
Deferred Taxes (CF)
-126.15MUSDFY2025 · Dec 31, 2025
Stock-based Compensation
58.28MUSDFY2025 · Dec 31, 2025
Other Non-cash Items
1.35MUSDFY2025 · Dec 31, 2025
Change in Accounts Receivable (CF)
1.69MUSDFY2025 · Dec 31, 2025
Change in Accounts Payable (CF)
-2.73MUSDFY2025 · Dec 31, 2025
Change in Other Assets/Liabilities
3.64MUSDFY2025 · Dec 31, 2025
Capital Expenditures
-909.00KUSDFY2025 · Dec 31, 2025
Purchase of Investments
-1.31BUSDFY2025 · Dec 31, 2025
Sale of Investments
1.22BUSDFY2025 · Dec 31, 2025
Net Investing Cash Flow
-85.05MUSDFY2025 · Dec 31, 2025
Net Financing Cash Flow
418.80MUSDFY2025 · Dec 31, 2025
Shares Outstanding
44.67MSharesUpdated Sep 27, 2026
Float Shares
34.30MSharesUpdated Sep 27, 2026
Shares Short
8.57MSharesUpdated Sep 27, 2026
Short Ratio
12.29days
vs all stocks
Updated Sep 27, 2026
Short % of Shares Outstanding
19.48%
vs all stocks
Updated Sep 27, 2026
% Held by Insiders
5.00%
vs all stocks
Updated Sep 27, 2026
% Held by Institutions
86.30%
vs all stocks
Updated Sep 27, 2026
Total Cash (MRQ)
861.61MUSD
vs all stocks (USD)
Updated Sep 27, 2026
Total Cash per Share (MRQ)
19.29USDUpdated Sep 27, 2026
Total Debt (MRQ)
91.31MUSD
vs all stocks (USD)
Updated Sep 27, 2026
Total Debt to Equity (MRQ)
0.0359x
vs Diagnostics & Research peers
Updated Sep 27, 2026
Current Ratio (MRQ)
10.95x
vs Diagnostics & Research peers
Updated Sep 27, 2026
Book Value per Share (MRQ)
56.93USDUpdated Sep 27, 2026
Total Assets
2.92BUSD
vs all stocks (USD)
FY2025 · Dec 31, 2025
Total Current Assets
953.85MUSDFY2025 · Dec 31, 2025
Total Liabilities
344.15MUSDFY2025 · Dec 31, 2025
Total Non-current Assets
1.97BUSDFY2025 · Dec 31, 2025
Total Non-current Liabilities
264.48MUSDFY2025 · Dec 31, 2025
Total Current Liabilities
79.67MUSDFY2025 · Dec 31, 2025
Cash & Cash Equivalents
249.73MUSDFY2025 · Dec 31, 2025
Other Short-term Investments
654.70MUSDFY2025 · Dec 31, 2025
Accounts Receivable
18.30MUSDFY2025 · Dec 31, 2025
Inventory
16.02MUSDFY2025 · Dec 31, 2025
Accounts Payable
2.08MUSDFY2025 · Dec 31, 2025
Short-term Debt
11.71MUSDFY2025 · Dec 31, 2025
Other Current Liabilities
1.93MUSDFY2025 · Dec 31, 2025
Long-term Debt
43.15MUSDFY2025 · Dec 31, 2025
Other Non-current Liabilities
2.75MUSDFY2025 · Dec 31, 2025
Common Stock (Book)
40.00KUSDFY2025 · Dec 31, 2025
Retained Earnings
-10.21BUSDFY2025 · Dec 31, 2025
Total Shareholders' Equity
2.58BUSD
vs all stocks (USD)
FY2025 · Dec 31, 2025
52-Week Low
41.50USDUpdated Sep 27, 2026
52-Week High
127.67USDUpdated Sep 27, 2026
52-Week Change
115.91%
vs all stocks
Updated Sep 27, 2026
Beta
3.25x
vs all stocks
Updated Sep 27, 2026
50-Day MA
77.14USDUpdated Sep 27, 2026
200-Day MA
72.47USDUpdated Sep 27, 2026
Avg 10-Day Volume
2.03MSharesUpdated Sep 27, 2026
Avg 30-Day Volume
1.09MSharesUpdated Sep 27, 2026
Diluted EPS (TTM)
-9.82USDUpdated Sep 27, 2026
Other Income / Expense
-28.99MUSDFY2025 · Dec 31, 2025
2 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Cash on hand covers most or all of its debt, and its equity share of assets is high for its industry.
Reads
Multi-Year Debt Decrease With Cash Near Total Debt And Equity
Long-term debt down in each of four years, and cash now covers most or all of what is left.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Gross margin is -28.1%, lower than 95% of its Diagnostics & Research peers (median 40.2%)Significant